Evidence map›Paper›PMID 38983961›Full record

ReviewWorld journal of gastroenterology2024

Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies.

Li-Li Yu, Zhi-Lin He, Xin-Lai Qian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Li-Li YuDepartment of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang 453003, Henan Province, China.
Zhi-Lin HeDepartment of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang 453003, Henan Province, China.
Xin-Lai QianDepartment of Pathology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Xinxiang 453003, Henan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are widely used due to their effectiveness in treating various tumors. Immune-related adverse events (irAEs) are defined as adverse effects resulting from ICI treatment. Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects, such as diarrhea and colitis, which may lead to the discontinuation of ICIs.

Indexed as

GastritisImmune Checkpoint InhibitorsHumansNeoplasmsImmune Checkpoint InhibitorsAutoimmune responsesImmune checkpoint inhibitorImmune checkpoint inhibitor-related gastritisImmune-related adverse eventsImmunotherapy

Identifiers

PMID38983961
PMCPMC11230054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.